HIV-I GP41 FUSION PEPTIDES FOR IMMUNOMODULALTION
    4.
    发明申请
    HIV-I GP41 FUSION PEPTIDES FOR IMMUNOMODULALTION 审中-公开
    HIV-I GP41用于免疫调节的融合肽

    公开(公告)号:US20090270312A1

    公开(公告)日:2009-10-29

    申请号:US11722064

    申请日:2006-01-24

    摘要: The present invention provides pharmaceutical compositions and methods for prevention or treatment of autoimmune diseases and other T cell mediated inflammatory diseases and conditions, which comprise as an active ingredient an effective quantity of a peptide derived from HIV gp41 fusion peptide domain or fragments, analogs, homologs and derivatives thereof. The invention further provides novel peptides derived from HIV gp41 fusion peptide domain, useful in the treatment of T cell mediated pathologies.

    摘要翻译: 本发明提供了用于预防或治疗自身免疫性疾病和其它T细胞介导的炎性疾病和病症的药物组合物和方法,其包含有效量的源自HIV gp41融合肽结构域或片段,类似物,同系物的有效成分 及其衍生物。 本发明还提供了衍生自HIV gp41融合肽结构域的新型肽,其可用于治疗T细胞介导的病理学。

    METHODS OF TREATING TUMORS IN IMMUNE-PRIVILEGED SITES
    7.
    发明申请
    METHODS OF TREATING TUMORS IN IMMUNE-PRIVILEGED SITES 有权
    在免疫特异性位点治疗肿瘤的方法

    公开(公告)号:US20100189750A1

    公开(公告)日:2010-07-29

    申请号:US12677543

    申请日:2008-09-11

    IPC分类号: A61K39/00 A61P35/00

    CPC分类号: A61K39/0011 A61K2039/5152

    摘要: A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject.

    摘要翻译: 提供了在有需要的受试者的免疫特异部位中治疗癌症的方法。 该方法包括系统地施用受试者的免疫特权部位之外的区域,治疗有效量的受试者肿瘤的天真,活的细胞,肿瘤位于免疫特异位点以产生免疫应答 从而治疗受试者的免疫特异部位的癌症。

    Inactivated CD8+ T-cells for the treatment of HIV infection
    8.
    发明授权
    Inactivated CD8+ T-cells for the treatment of HIV infection 失效
    用于治疗HIV感染的灭活CD8 + T细胞

    公开(公告)号:US07740855B2

    公开(公告)日:2010-06-22

    申请号:US11290682

    申请日:2005-11-30

    IPC分类号: A61K39/00

    摘要: A method for the preparation of a T cell vaccine for the treatment of immunodeficient HIV-infected patients is described herein, based on the enrichment of autologous CD4-reactive CD8 T cells. Also described is a protocol for the implementation of T cell vaccination in immunodeficient HIV-infected, as well as a method of treatment, based on the T cell vaccine developed herein. Finally, kits for preparing the T cell vaccine as well as for implementing the protocol are also provided.

    摘要翻译: 基于自体CD4反应性CD8T细胞的富集,本文描述了用于制备用于治疗免疫缺陷型HIV感染患者的T细胞疫苗的方法。 还描述了用于在免疫缺陷型HIV感染中实施T细胞疫苗接种的方案,以及基于本文开发的T细胞疫苗的治疗方法。 最后,还提供了用于制备T细胞疫苗以及实施方案的试剂盒。

    VACCINES COMPRISING MULTIMERIC HSP60 PEPTIDE CARRIERS
    9.
    发明申请
    VACCINES COMPRISING MULTIMERIC HSP60 PEPTIDE CARRIERS 失效
    包含多种HSP60肽载体的疫苗

    公开(公告)号:US20090269370A1

    公开(公告)日:2009-10-29

    申请号:US12296428

    申请日:2007-04-11

    摘要: The present invention provides improved vaccine compositions having enhanced immunogenicity and methods of using same. The compositions and methods include immunogenic conjugates containing peptide carriers derived from heat shock protein 60 (HSP60). The known synthetic peptide carrier, p458, provides significantly improved immunogenicity when provided as a multimeric conjugate comprising a plurality of peptide carrier units conjugated to each antigen. Cell vaccine compositions comprising antigen presenting cells loaded with multimeric p458 conjugates are also provided.

    摘要翻译: 本发明提供具有增强的免疫原性的改进的疫苗组合物及其使用方法。 组合物和方法包括含有衍生自热休克蛋白60(HSP60)的肽载体的免疫原性缀合物。 当作为包含与每个抗原缀合的多个肽载体单元的多聚体缀合物提供时,已知的合成肽载体p458提供显着改善的免疫原性。 还提供了包含负载有多聚体p458缀合物的抗原呈递细胞的细胞疫苗组合物。